News

Enlarge image

BusinessBelgium

UCB partners with Five Prime

20.03.2013 - Belgian UCB S.A. and US-based biologics specialist Five Prime Therapeutics have entered into a drug discovery collaboration.

The companies will screen for new targets and therapeutics in the areas of fibrosis-related inflammatory diseases and central nervous system (CNS) disorders. Under the terms of the agreement, UCB will gain exclusive access to FivePrime's library of 5.600 functionally secreted proteins and receptor proteins in up to five programmes to identify new targets and disease mechanisms.   

FivePrime will receive US$16m for providing its library and screening platform, a combination of an upfront fee, technology access fees, research funding and success-based research milestone payments. UCB has an option to license exclusively rights to selected protein targets discovered by FivePrime within the collaboration. In addition, FivePrime would be eligible for potential option exercise fees and product-related milestone payments, as well as tiered royalties on global net sales on future products related to each licensed protein.  

Further financial details are subject to a confidentially agreement.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/ucb-partners-with-five-prime-therapeutics.html

Clinical TrialsFrance

26.08.2016 Adocia said it would discontinue its diabetic foot ulcer programme after its lead product BioChaperone PDGF disappointed in Phase III. The French company will turn the focus on its earlier-stage products.

M&AUKSweden

24.08.2016 Pharma major Pfizer is putting the cherry on top of its multi-billion-dollar takeover of Medivation with the acquisition of AstraZeneca’s antibiotics for a cool US$1.5bn. With the divestment, AZ aims to further sharpen its focus.

FinancingUK

23.08.2016 Cambridge University-allied investor Cambridge Innovation Capital has raised £75m (€87m) to reinvest in technology and healthcare companies. Among the backers were Woodford Investment and Winton Ventures.

R&DDenmark

19.08.2016 Together with partner Johnson & Johnson, Danish biotech Genmab is now one step closer to FDA approval with its combination treatment for multiple myeloma after its submission of a supplemental Biologics License Application. In July, Genmab was granted a Breakthrough Therapy Designation (BTD) for its blood cancer therapy.

ResearchUKEU

17.08.2016 Philip Hammond, the UK’S chancellor has announced the government will guarantee funding for EU-backed "structural and investment fund" projects whose timelines extend beyond the UK’s departure from the EU, provided the projects are signed prior to this year's Autumn Statement on the UK budget. The decision ensures continued funding for farmers, companies and institutions involved in the EU’s Horizon 2020 project. The move could cost the UK government up to £6bn (€6.9bn).

Stock marketsGermany

15.08.2016 Back in April, the American FDA gave the green light for the colorectal cancer-screening test Epi procolon. Now Berlin-based diagnostics specialist Epigenomics is considering a secondary listing in the US. A draft of the required registration document was confidentially submitted to the US Securities and Exchange Commission (SEC).

LicensingDenmark

11.08.2016 Danish Genmab AS has granted Gilead Sciences license to use its DuoBody technology platform to develop bispecific antibodies for the treatment of HIV. The deal is worth up to €252m.

Clinical developmentHungaryIreland

09.08.2016 Hungarian Gedeon Richter and Irish Allergan are staying on course in the face of dissappointing Phase III results for depression drug cariprazine. The partners will now begin another Phase III study needed for approval.

ImmunotherapySpain

08.08.2016 Araclon Biotech’s Alzheimer’s vaccine ABvac40 is going forward into Phase II after showing a good safety profile in Phase I. The promising trial results were presented at the Alzheimer’s Association International Conference.

ApprovalEU

04.08.2016 After a two-year pilot period, the EMA has published its report on its adaptive pathways approach. The agency plans to “explore the concept further” and will continue to accept proposals.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • NORDIC NANOVECTOR (N)34.00 NOK6.58%
  • RENEURON (UK)2.88 GBP4.73%
  • SUMMIT (UK)4.03 GBP3.87%

FLOP

  • SWEDISH ORPHAN BIOVITRUM (S)11.56 USD-7.52%
  • VITA 34 (D)4.14 EUR-7.17%
  • ADOCIA (F)53.20 EUR-5.67%

TOP

  • DIAMYD MEDICAL -B- (S)6.90 SEK59.7%
  • NORDIC NANOVECTOR (N)34.00 NOK39.3%
  • KARO BIO (S)42.00 SEK36.4%

FLOP

  • BIONOR PHARMA (N)0.44 NOK-25.4%
  • MOLOGEN (D)1.78 EUR-22.6%
  • WILEX (D)1.47 EUR-15.0%

TOP

  • NICOX (F)10.07 EUR430.0%
  • SAREUM HOLDINGS (UK)0.76 GBP245.5%
  • GENMAB (DK)1094.00 DKK79.3%

FLOP

  • BB BIOTECH (D)44.29 EUR-83.5%
  • EVOCUTIS (UK)0.04 GBP-80.0%
  • CIRCASSIA LIMITED (L)92.00 GBP-72.0%

No liability assumed, Date: 26.08.2016